JPM Is A Record-Earning Machine That's Finally Too Damn Expensive

# JPM Is A Record-Earning Machine That's Finally Too Damn Expensive

Let's get the elephant out of the trading room first: JPMorgan just posted a quarter that would make most banks weep. Q2 2026 net revenue came in around $57.3 billion, up roughly 28% year over year. Net income was $21.2 billion. Wells Fargo hiked its target to $390. Management raised its full-year net interest income guide to about $105.5 billion and bumped the dividend to $1.65 a share. On paper this is a five-star franchise operating at a five-star price.

Here's the thing nobody wants to say out loud: the good news is the problem.

Take a close look at that $21.2 billion. Nearly $4.6 billion of it was a Visa gain. On top of that, about $1 billion in equity gains. Strip the one-offs and management applied a $4.2 billion after-tax adjustment, which collapsed adjusted EPS from $7.70 down to $6.14 and knocked adjusted ROTCE down six points to 23%. That's not a blip. That's the headline number losing a third of its substance. Call it what it is: a record quarter that was mostly record in name only.

I'm not saying JPMorgan is a bad business. It isn't. It's the fort-grade monster with $5 trillion in assets, $375 billion in equity, and net margins most firms would kill for. But a business can be wonderful and its stock can still be a bad purchase, and that is exactly where JPM sits right now.

The stock has been hovering in a $338 to $356 band all September, sitting just under its 52-week high and just below consensus targets. The average 12-month target is around $360, which implies basically no upside from here. Meanwhile, independent valuation models are flagging the stock as roughly 9% to 10% overvalued — a fair-value estimate near $317.50 against a price near $350. The trailing P/E of about 15 is sitting well above its own five-year median of roughly 11.5. You are paying a premium multiple for earnings that, stripped of the gimmicks, are not that much better than normal.

And then there's the date that owns this entire trade: October 13.

JPMorgan reports Q3 2026 earnings at 7:00 a.m. ET on Tuesday, October 13, with the call at 8:30. This is the dominant swing factor, and the setup is ugly. Q3 EPS estimates range from $5.06 to $5.91 — a nearly dollar-wide gap in what the Street thinks. Full-year 2026 estimates stretch from $22.4 to $25.0. That is not a consensus; that's a crowd of people who genuinely don't agree and will all be wrong at once in one direction or the other. Binary event. Expected gap. Expected IV crush.

Now layer the technicals on top, because they don't help. The stock has given back about 5% over the past month, sits 3% below its 20-day and 50-day averages, and its 14-day RSI is at 35 — oversold, yes, but not the kind of oversold that guarantees a bounce. The model's own forecast points to a near-term dip toward $307, with a floor band that gets uncomfortably deep. Support is around the $320 SMA200 zone; the $307 floor is where faith goes to die.

So what's the actual read? The fundamentals are strong and I respect the franchise. The valuation is rich. The catalyst is a coin-flip. The tape is soft. Chasing JPM here, into a wide-dispersion earnings print at an expensive multiple, is how you buy a lottery ticket and call it an investment.

My approach would be to let the tape come to you. Build in trims rather than dumping size in at once: accumulate near the $320 SMA200 support, and be ready to add harder toward that $307 forecast floor if the October print — or the macro noise around it — forces a gap. Don't size into earnings. The market will give you a better price and a clearer read after the 8:30 a.m. call, not before.

The bear case is simple and I'll defend it: rich multiple, non-recurring earnings propping up the headline, NII still directionally uncertain (remember, they cut the guide in Q1 before raising it in Q2), and energy-credit exposure tied to oil and the global rate cycle. The bull case is equally simple: fee diversification, a balance sheet that could absorb a recession, and a management team that has repeatedly come in on the right side of estimates. Both are true. The stock just won't let you have the easy version of either.

Here's the close: JPMorgan is a top-tier business trading at a top-tier price into a top-tier binary event. That combination doesn't beg to be chased. It begs to be waited out. Patience isn't the polite word for being too timid to act — sometimes it's the only act worth making. Let the October 13 tape tell you the story, buy the support if it holds, and let the over-payers get burned.